Tamiflu review raises questions

Share this article:

A systematic review of Roche's antiviral drug Tamiflu appearing in last month's Cochrane Library has led to questions about the data's efficacy, as well as Roche's commitment to provide sufficient data.

“We found a high risk of publication and reporting biases in the trial programme of [Tamiflu],” Cochrane Collaboration researchers wrote.

Evidence confirms Tamiflu shortened length of symptoms vs. placebo. Other findings question its mechanism of action but could not be properly assessed without access to the full document set. The paper “has raised challenges for all those engaged in conducting systematic reviews,” wrote Cochrane editors.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.